DK0804933T3 - Lagerstabile fibrinogenpræparater - Google Patents
Lagerstabile fibrinogenpræparaterInfo
- Publication number
- DK0804933T3 DK0804933T3 DK97106568T DK97106568T DK0804933T3 DK 0804933 T3 DK0804933 T3 DK 0804933T3 DK 97106568 T DK97106568 T DK 97106568T DK 97106568 T DK97106568 T DK 97106568T DK 0804933 T3 DK0804933 T3 DK 0804933T3
- Authority
- DK
- Denmark
- Prior art keywords
- fbg
- acid
- lyophilised
- vitamin
- pyridine
- Prior art date
Links
- 108010049003 Fibrinogen Proteins 0.000 title abstract 9
- 102000008946 Fibrinogen Human genes 0.000 title abstract 9
- 229940012952 fibrinogen Drugs 0.000 title abstract 9
- 238000002360 preparation method Methods 0.000 title abstract 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 abstract 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 102000009123 Fibrin Human genes 0.000 abstract 2
- 108010073385 Fibrin Proteins 0.000 abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- 229950003499 fibrin Drugs 0.000 abstract 2
- 231100001083 no cytotoxicity Toxicity 0.000 abstract 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 abstract 2
- 229940011671 vitamin b6 Drugs 0.000 abstract 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 abstract 1
- ZHBYCCVSWKWSMR-UHFFFAOYSA-N 2-hydroperoxybenzoic acid Chemical compound OOC1=CC=CC=C1C(O)=O ZHBYCCVSWKWSMR-UHFFFAOYSA-N 0.000 abstract 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N Pyrocatechuic acid Natural products OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 229960004050 aminobenzoic acid Drugs 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 235000011148 calcium chloride Nutrition 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 125000000371 nucleobase group Chemical group 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 229940081066 picolinic acid Drugs 0.000 abstract 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 abstract 1
- 229960004919 procaine Drugs 0.000 abstract 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- KZVLNAGYSAKYMG-UHFFFAOYSA-N pyridine-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=N1 KZVLNAGYSAKYMG-UHFFFAOYSA-N 0.000 abstract 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N pyridinedicarboxylic acid Natural products OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 235000008160 pyridoxine Nutrition 0.000 abstract 1
- 239000011677 pyridoxine Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000010257 thawing Methods 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 239000003106 tissue adhesive Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19617369A DE19617369A1 (de) | 1996-04-30 | 1996-04-30 | Lagerstabile Fibrinogen-Präparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK0804933T3 true DK0804933T3 (da) | 2004-05-17 |
| DK0804933T4 DK0804933T4 (da) | 2009-06-02 |
Family
ID=7792949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97106568T DK0804933T4 (da) | 1996-04-30 | 1997-04-21 | Lagerstabile fibrinogenpræparater |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5962405A (da) |
| EP (1) | EP0804933B2 (da) |
| JP (1) | JP4094701B2 (da) |
| AT (1) | ATE263586T1 (da) |
| CA (1) | CA2203961C (da) |
| DE (2) | DE19617369A1 (da) |
| DK (1) | DK0804933T4 (da) |
| ES (1) | ES2218615T5 (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT407117B (de) * | 1997-09-19 | 2000-12-27 | Immuno Ag | Fibrinschwamm |
| DE19853033A1 (de) * | 1998-11-18 | 2000-05-25 | Centeon Pharma Gmbh | Stabilisierte Proteinzubereitung für einen Gewebekleber |
| AU773128B2 (en) * | 1998-11-18 | 2004-05-20 | Csl Behring Gmbh | Stabilised protein preparations for a tissue adhesive |
| US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
| JP4771594B2 (ja) * | 1999-02-12 | 2011-09-14 | バクスター アクチェンゲゼルシャフト | フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物 |
| EP1151007B1 (en) * | 1999-02-12 | 2006-05-03 | Baxter Aktiengesellschaft | A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method |
| US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| KR20040055782A (ko) * | 2001-10-03 | 2004-06-26 | 크리스토퍼 제이 울버튼 | 보관-안정한 인간 피브리노겐 용액 |
| KR20050044725A (ko) * | 2001-12-04 | 2005-05-12 | 크리스토퍼 제이 울버튼 | 저장-안정성 피브린 밀봉제 |
| US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| EP2335650B1 (en) | 2003-12-11 | 2012-10-03 | Isto Technologies Inc. | Particulate cartilage system |
| US20070014780A1 (en) * | 2005-07-13 | 2007-01-18 | Statseal | Storage-stable human fibrinogen solutions |
| CN1911440A (zh) * | 2005-08-08 | 2007-02-14 | 上海莱士血制品有限公司 | 一种用于形成纤维蛋白膜的试剂盒及其应用 |
| JP5292533B2 (ja) | 2005-08-26 | 2013-09-18 | ジンマー・インコーポレイテッド | インプラントおよび関節疾患の治療、置換および治療方法 |
| US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
| MX2009007688A (es) * | 2007-01-18 | 2009-09-28 | Baxter Int | Gel de fibrina para liberacion controlada de tgp-beta y usos del mismo. |
| EP2134297B1 (en) | 2007-04-12 | 2017-03-08 | Zimmer, Inc. | Apparatus for tissue repair |
| BRPI0812718A2 (pt) * | 2007-06-19 | 2014-12-23 | Baxter Int | Métodos para modificar a liberação de uma proteína do fator de crescimento derivado de plaqueta, para modificar a liberação de um fator de crescimento derivado de plaqueta, para a liberação de uma proteína do fator de crescimento derivado de plaqueta e para tratar um paciente que sobre de um distúrbio ou doença, kit, e, uso de um selante de fibrina |
| WO2010006219A2 (en) * | 2008-07-09 | 2010-01-14 | Baxter International Inc. | Use of scaffold comprising fibrin for delivery of stem cells |
| TWI488662B (zh) | 2008-12-11 | 2015-06-21 | Baxter Int | 基於血纖維蛋白元與硫酸化多醣的製劑 |
| CA2786527A1 (en) * | 2010-01-08 | 2011-07-14 | Baxter International Inc. | Biomatrices to attract and retain regenerative and reparative cells |
| ES2513516T3 (es) | 2010-01-28 | 2014-10-27 | Omrix Biopharmaceuticals Ltd. | Método para un sellado con fibrina mejorado |
| EP2624823A4 (en) | 2010-09-23 | 2016-08-03 | Inflammagen | ADMINISTRATION OF SERIN PROTEASE INHIBITORS IN THE STOMACH |
| KR101127127B1 (ko) * | 2011-10-27 | 2012-03-21 | 주식회사 녹십자 | 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법 |
| US10618950B2 (en) | 2011-12-29 | 2020-04-14 | Omrix Biopharmaceuticals Ltd. | Method and device for fast dissolution of solid protein composition |
| CA2866828C (en) | 2012-03-12 | 2022-09-06 | Hobart W. HARRIS | Methods and compositions for treating wounds and reducing the risk of incisional hernias |
| US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| CA2942358C (en) | 2014-03-25 | 2023-03-28 | Leading BioSciences, Inc. | Compositions for the treatment of autodigestion |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CA3010986A1 (en) | 2016-01-11 | 2017-07-20 | Leading BioSciences, Inc. | Compositions and methods for treating and preventing adhesions and ileus |
| DE102017105256A1 (de) * | 2017-03-13 | 2018-09-13 | Rudolf W. Strümper | Behandlung einer Ruptur eines Körperbestandteils |
| JP2024529107A (ja) | 2021-08-13 | 2024-08-01 | ビオテスト・アクチエンゲゼルシャフト | フィブリノゲン組成物および調製方法 |
| EP4456935A1 (en) | 2021-12-30 | 2024-11-06 | Baxter International Inc. | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
| CN115436647B (zh) * | 2022-09-20 | 2025-05-13 | 上海太阳生物技术有限公司 | 纤维蛋白原质控品及其制备方法与应用 |
| CN115494247B (zh) * | 2022-09-20 | 2025-05-13 | 上海太阳生物技术有限公司 | 凝血酶时间质控品及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT359653B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| AT359652B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| AT371719B (de) * | 1980-08-25 | 1983-07-25 | Immuno Ag | Verfahren und vorrichtung zur beschleunigung des aufloesens von schwerloeslichen lyophilisierten arzneimitteln |
| AT369990B (de) * | 1981-07-28 | 1983-02-25 | Immuno Ag | Verfahren zur herstellung eines gewebeklebstoffes |
| DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
| AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| AT379311B (de) * | 1984-03-29 | 1985-12-27 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
| AT397203B (de) * | 1988-05-31 | 1994-02-25 | Immuno Ag | Gewebeklebstoff |
| AT396548B (de) * | 1990-05-03 | 1993-10-25 | Immuno Ag | Biopsieeinrichtung |
| AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| US5290918A (en) † | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
| US5330974A (en) * | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
-
1996
- 1996-04-30 DE DE19617369A patent/DE19617369A1/de not_active Ceased
-
1997
- 1997-04-21 AT AT97106568T patent/ATE263586T1/de active
- 1997-04-21 DE DE59711487T patent/DE59711487D1/de not_active Expired - Lifetime
- 1997-04-21 ES ES97106568T patent/ES2218615T5/es not_active Expired - Lifetime
- 1997-04-21 EP EP97106568A patent/EP0804933B2/de not_active Expired - Lifetime
- 1997-04-21 DK DK97106568T patent/DK0804933T4/da active
- 1997-04-23 US US08/838,975 patent/US5962405A/en not_active Expired - Lifetime
- 1997-04-29 CA CA002203961A patent/CA2203961C/en not_active Expired - Fee Related
- 1997-04-30 JP JP11213797A patent/JP4094701B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0804933B1 (de) | 2004-04-07 |
| ES2218615T5 (es) | 2009-07-03 |
| EP0804933A2 (de) | 1997-11-05 |
| JPH1036286A (ja) | 1998-02-10 |
| US5962405A (en) | 1999-10-05 |
| ATE263586T1 (de) | 2004-04-15 |
| DK0804933T4 (da) | 2009-06-02 |
| ES2218615T3 (es) | 2004-11-16 |
| EP0804933A3 (de) | 2000-03-22 |
| DE19617369A1 (de) | 1997-11-06 |
| CA2203961C (en) | 2008-07-08 |
| CA2203961A1 (en) | 1997-10-30 |
| JP4094701B2 (ja) | 2008-06-04 |
| DE59711487D1 (de) | 2004-05-13 |
| EP0804933B2 (de) | 2009-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0804933T4 (da) | Lagerstabile fibrinogenpræparater | |
| Elg et al. | Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor | |
| Stern et al. | Endothelium and regulation of coagulation | |
| Fenton et al. | Thrombin and antithrombotics | |
| Marder et al. | Hemostasis and thrombosis: basic principles and clinical practice | |
| Kimball | Challenges in the development of orally bioavailable thrombin active site inhibitors | |
| Bauer et al. | Mechanism of thrombin binding to endothelial cells | |
| DE59913287D1 (de) | Stabilisierte proteinzubereitungen für einen gewebekleber | |
| DK36991A (da) | Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren | |
| Markland et al. | Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. | |
| Potapov et al. | Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device | |
| Fenton II | Thrombin functions and antithrombotic intervention | |
| Toschi et al. | Biochemistry and biology of hirudin | |
| Esmon et al. | Interaction of thrombin with thrombomodulin | |
| ES2064435T3 (es) | Aceleracion de la lisis de los coagulos. | |
| Shimada et al. | Histidine-rich glycoprotein does not interfere with interactions between antithrombin III and heparin-like compounds on vascular endothelial cells | |
| Maraganore | Pre-clinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor | |
| NO904119D0 (no) | Trombolytisk materiale inneholdende vevstypeplasminogenaktivator eller derivat derav. | |
| Hoffman et al. | Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III | |
| Fry et al. | The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators | |
| Eisenberg | Novel antithrombotic strategies for the treatment of coronary artery thrombosis: a critical appraisal | |
| Hobbiger et al. | The relationship between the level of cholinesterase in plasma and the action of suxamethonium in animals | |
| Ohri et al. | Genetically engineered serine protease inhibitor for hemostasis after cardiac operations | |
| Becker | Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis | |
| Kumar et al. | Thrombin formation |